GLP-1 medications should be prescribed and monitored by a qualified medical provider
As a GLP-1 receptor agonist, it works by mimicking the natural incretin hormone GLP-1 to increase insulin secretion in a glucose-dependent manner, suppress glucagon release, slow gastric emptying by approximately 35%, and reduce appetite through central nervous system signaling
Another provider prescribed 20 units instead of 2, affecting three patients who, after receiving 10 times the intended dose, experienced nausea and vomiting
The maximum retatrutide dose currently being studied in major Phase 3 obesity trials is 12mg once weekly
There are no subscriptions or ongoing commitments
Once the mechanism works, the question shifts from who can build it to who controls it, and that's where most teams are underprepared." Across the landscape: Novo Nordisk is building across multiple triple-agonist assets Pfizer has entered through acquisition Hanmi is advancing the only clinical-stage small-molecule triple Innovent, Hengrui, and multiple Chinese sponsors are scaling pipeline depth Sanofi holds the largest IP position without a disclosed asset 27 programs
